Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY 1.5/30 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life of ethinyl estradiol is 13-27 hours (mean 17 hours); for norgestimate, active metabolite norelgestromin has half-life 12-30 hours (mean 19 hours). Steady state reached after 7-14 days.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol undergoes hepatic metabolism primarily via CYP3A4; desogestrel is rapidly metabolized to its active metabolite etonogestrel via hydroxylation and dehydrogenation, further metabolized via CYP2C9 and CYP3A4.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Approximately 40% renal (as metabolites), 32% fecal (as metabolites), and <1% unchanged in urine.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Ethinyl estradiol: ~98% bound to albumin; norelgestromin: ~99% bound to albumin and SHBG.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Ethinyl estradiol: 2.3-4.0 L/kg; norelgestromin: 2.0-3.5 L/kg. Indicates extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: Ethinyl estradiol 40-55% (first-pass metabolism); norelgestromin: ~80% (as metabolite of norgestimate).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe impairment, but estrogen metabolites may accumulate; use caution.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in acute liver disease or severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use is not recommended due to altered hormone clearance; if used, monitor liver function and consider lower estrogen dose.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Postmenarchal adolescents: Same adult dosing (one tablet daily). Safety and efficacy not established in premenarchal girls.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for postmenopausal women; contraindicated after menopause due to increased risk of cardiovascular events. No specific geriatric dose.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Cigarette smoking increases cardiovascular risk,Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Carbohydrate and lipid effects,Ocular lesions,Headache/migraine,Bleeding irregularities,Depression
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Active or history of venous thromboembolism,Cerebrovascular disease,Coronary artery disease,Valvular heart disease with complications,Thrombogenic valvulopathies,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Uncontrolled hypertension,Active liver disease,Known or suspected pregnancy,Breast cancer or other estrogen-sensitive neoplasia,Heavy smoking (≥15 cigarettes/day) and age ≥35
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. A high-fat meal may delay absorption but does not reduce efficacy. Avoid excessive alcohol as it may increase liver enzymes and theoretically reduce efficacy.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
FDA Pregnancy Category X. Combined hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of fetal malformations; however, CHCs should be discontinued if pregnancy occurs. Second and third trimester exposure may increase risks of fetal adverse outcomes, including but not limited to congenital anomalies and fetal demise. Use is not recommended at any trimester.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
CHCs may reduce milk production and composition. Small amounts of synthetic estrogen and progestin are excreted in breast milk. M/P ratio not specifically reported for this combination; ethinyl estradiol M/P ratio approximately 0.02-0.05. Use during lactation is generally not recommended, especially in early postpartum period. Alternative contraception should be considered.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Contraindicated in pregnancy; no dose adjustments applicable as drug should be discontinued immediately upon confirmed pregnancy. Pharmacokinetic changes during pregnancy (e.g., increased clearance) are not relevant given contraindication.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
HAILEY 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and levonorgestrel 1.5 mg. It is a monophasic pill with 21 active tablets. Counsel patients that missed pills increase pregnancy risk, especially if more than one active pill is missed. Use back-up contraception for 7 days if a dose is missed. Consider increased risk of venous thromboembolism (VTE) in smokers over 35, obese patients, or those with thrombophilia. Nausea may be reduced by taking with food or at bedtime. Spotting is common in first 3 cycles; if persistent, rule out pregnancy or other causes.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one pill daily at the same time for 21 days, then 7 placebo pills.,If you miss a pill, follow the package insert instructions for missed doses and use back-up contraception (e.g., condoms) for 7 days.,Do not smoke while taking this medication, especially if over age 35, due to increased risk of blood clots.,Common side effects include nausea, breast tenderness, and spotting, which usually improve after 3 cycles.,Seek immediate medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,Antibiotics (except rifampin) do not reduce effectiveness; however, certain drugs like rifampin, griseofulvin, and some anticonvulsants may decrease efficacy.,Store at room temperature, away from moisture and heat.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HAILEY 1.5/30 vs ALTAVERA, answered by our medical review team.
HAILEY 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HAILEY 1.5/30 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HAILEY 1.5/30 is: One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HAILEY 1.5/30 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HAILEY 1.5/30 is classified as Category C. FDA Pregnancy Category X. Combined hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of fetal malformations; h. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.